Seeking Alpha

Pfizer (PFE) lost a bid to overturn a ruling awarding Kaiser Foundation Health Plan $142M in...

Pfizer (PFE) lost a bid to overturn a ruling awarding Kaiser Foundation Health Plan $142M in connection with the marketing and prescribing of Neurontin for conditions other than those the drug was approved to treat. The court also resurrected claims from other plaintiffs. 
Comments (2)
  • sethmcs
    , contributor
    Comments (3128) | Send Message
     
    The root of this problem is a doctor can prescribe a laxative for a headache. Unapproved use will contine until there are clear rules for doctors to follow.
    4 Apr 2013, 01:32 AM Reply Like
  • Desperado2012
    , contributor
    Comments (91) | Send Message
     
    The fact is that doctors CAN prescribe medicine for unapproved indications, but the drug companies are not allowed to promote that use. With Neurontin it is understandable that it is being used treating unapproved indications relating to nerve damage. For Pfizer to go trough clinical trials and approvals for each potentially treatable indication would cost them more than the use would bring in. I don't know the case of Kaiser Health Plan's complaint, but to me it seems that the ruling should have been overturned - the award is hefty for a Foundation Health Plan, suing only in hopes of making money for the Foundation.
    4 Apr 2013, 06:20 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|